A series of diaryltriazines and diarylpyrimidines are highly potent nonnucleoside reverse transcriptase inhibitors with possible applications as microbicides

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 10, 2004, Pages 3684-3689

  Van Herrewege, Yven ^a   Vanham, Guido ^a,b   Michiels, Jo ^a   Fransen, Katrien ^a   Kestens, Luc ^a   Andries, Koen ^c   Janssen, Paul ^d   Lewi, Paul ^d  

^a INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^b UNIVERSITY OF ANTWERP   (Belgium)

^c Virco BVBA   (Belgium)

^d Center for Molecular Design   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIGEN P24; ANTIINFECTIVE AGENT; CD4 ANTIGEN; DAPIVIRINE; ETRAVIRINE; INTERLEUKIN 2; N [4 CHLORO 3 (3 METHYL 2 BUTENYLOXY)PHENYL] 2 METHYL 3 FURANCARBOTHIOAMIDE; PHYTOHEMAGGLUTININ; PYRIMIDINE DERIVATIVE; R 151694; R 152649; R 152929; R 153430; R 302730; R 312924; RILPIVIRINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; TRIAZINE DERIVATIVE; UNCLASSIFIED DRUG; VIRUS DNA;

ANTIVIRAL ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DENDRITIC CELL; DRUG INDICATION; DRUG POTENCY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; MIXED LEUKOCYTE CULTURE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; T LYMPHOCYTE; VIRUS CULTURE;

ANTI-INFECTIVE AGENTS; CD4-POSITIVE T-LYMPHOCYTES; HIV ANTIGENS; HUMANS; PYRIMIDINES; REVERSE TRANSCRIPTASE INHIBITORS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRIAZINES;

EID: 4644252952     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.10.3684-3689.2004     Document Type: Article

References (30)

1. Beirnaert, E., B. Willems, M. Peeters, A. Bouckaert, L. Heyndrickx, P. Zhong, K. Vereecken, S. Coppens, D. Davis, P. Ndumbe, W. Janssens, and G. van der Groen. 1998. Design and evaluation of an in-house HIV-1 (group M and O) SIVmnd and SIVcpz antigen capture assay. J. Virol. Methods 73:65-70.
2. Bernasconi, E. 1999. Metabolic effects of protease inhibitor therapy. AIDS Read. 9:254-266.
3. Calza, L., R. Manfredi, and F. Chiodo. 2003. Hyperlipidaemia in patients with HIV-1 infection receiving highly active antiretroviral therapy: epidemiology, pathogenesis, clinical course, and management. Int. J. Antimicrob. Agents 22:89-99.
4. Carr, A., K. Samaras, D. J. Chisholm, and D. A. Cooper. 1998. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 351:1881-1883.
5. Christopherson, C., Y. Kidane, B. Conway, J. Krowka, H. Sheppard, and S. Kwok. 2000. PCR-Based assay to quantify human immunodeficiency virus type 1 DNA in peripheral blood mononuclear cells. J. Clin. Microbiol. 38:630-634.
6. D'Aquila, R. T., M. D. Hughes, V. A. Johnson, M. A. Fischl, J. P. Sommadossi, S. H. Liou, J. Timpone, M. Myers, N. Basgoz, M. Niu, M. S. Hirsch, et al. 1996. Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection: a randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 124:1019-1030.
7. Di Fabio, S., J. Van Roey, G. Giannini, G. van den Mooter, M. Spada, A. Binelli, M. F. Pirillo, E. Germinario, F. Belardelli, M. P. de Bethune, and S. Vella. 2003. Inhibition of vaginal transmission of HIV-1 in hu-SCID mice by the non-nucleoside reverse transcriptase inhibitor TMC120 in a gel formulation. AIDS 17:1597-1604.
8. Hu, J., M. B. Gardner, and C. J. Miller. 2000. Simian immunodeficiency virus rapidly penetrates the cervicovaginal mucosa after intravaginal inoculation and infects intraepithelial dendritic cells. J. Virol. 74:6087-6095.
9. Kaufmann, G. R., and D. A. Cooper. 2000. Antiretroviral therapy of HIV-1 infection: established treatment strategies and new therapeutic options. Curr. Opin. Microbiol. 3:508-514.
10. Kawamura, T., S. S. Cohen, D. L. Bonis, E. A. Aquiline, S. Glushakova, L. B. Margolis, J. M. Orenstein, R. E. Offord. A. R. Neurath, and A. Blauvelt. 2000. Candidate microbicides block HIV-1 infection of human immature Langerhans cells within epithelial tissue explants. J. Exp. Med. 192:1491-1500.
11. Ludovici, D. W., B. L. De Corte, M. J. Kukla, H. Ye, C. Y. Ho, M. A. Lichtenstein, R. W. Kavash, K. Andries, M. P. de Bethune, H. Azijn, R. Pauwels, P. J. Lewi, J. Heeres, L. M. Koymans, M. R. de Jonge, K. J. Van Aken, F. F. Daeyaert, K. Das, E. Arnold, and P. A. Janssen. 2001. Evolution of anti-HIV drug candidates. 3. Diarylpyrimidine (DAPY) analogues. Bioorg. Med. Chem. Lett. 11:2235-2239.
12. Ludovici, D. W., R. W. Kavash, M. J. Kukla, C. Y. Ho, H. Ye, B. L. De Corte, K. Andries, M. P. de Bethune, H. Azijn, R. Pauwels, H. E. Moereels, J. Heeres, L. M. Koymans, M. R. de Jonge, K. J. Van Aken, F. F. Daeyaert, P. J. Lewi, K. Das, E. Arnold, and P. A. Janssen. 2001. Evolution of anti-HIV drug candidates. 2. Diaryltriarine (DATA) analogues. Bioorg. Med. Chem. Lett. 11:2229-2234.
13. Luzuriaga, K., Y. Bryson, P. Krogstad, J. Robinson, B. Stechenberg, M. Lamson, S. Cort, and J. L. Sullivan. 1997. Combination treatment with zidovudine, didanosine, and nevirapine in infants with human immunodeficiency virus type 1 infection. N. Engl. J. Med. 336:1343-1349.
14. Masurier, C., B. Salomon, N. Guettari, C. Pioche, F. Lachapelle, M. Guigon, and D. Klatzmann. 1998. Dendritic cells route human immunodeficiency virus to lymph nodes after vaginal or intravenous administration to mice. J. Virol. 72:7822-7829.
15. Matsushita, S. 2000. Current status and future issues in the treatment of HIV-1 infection. Int. J. Hematol. 72:20-27.
16. Milman, G., and O. Sharma. 1994. Mechanisms of HIV/SIV mucosal transmission. AIDS Res. Hum. Retrovir. 10:1305-1312.
17. Montaner, J. S., P. Reiss, D. Cooper, S. Vella, M. Harris, B. Conway, M. A. Wainberg, D. Smith, P. Robinson, D. Hall, M. Myers, and J. M. Lange. 1998. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS trial. JAMA 279:930-937.
18. Pialoux, G., F. Raffi, F. Brun-Vezinet, V. Meiffredy, P. Flandre, J. A. Gastaut, P. Dellamonica, P. Yeni, J. F. Delfraissy, J. P. Aboulker, et al. 1998. A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients. N. Engl. J. Med. 339:1269-1276.
19. + T cells. J. Exp. Med. 182:2045-2056.
20. Reece, J. C., A. J. Handley, E. J. Anstee, W. A. Morrison, S. M. Crowe, and P. U. Cameron. 1998. HIV-1 selection by epidermal dendritic cells during transmission across human skin. J. Exp. Med. 187:1623-1631.
21. Romani, N., S. Gruner, D. Brang, E. Kampgen, A. Lenz, B. Trockenbacher, G. Konwalinka, P. O. Fritsch, R. M. Steinman, and G. Schuler. 1994. Proliferating dendritic cell progenitors in human blood. J. Exp. Med. 180:83-93.
22. Sallusto, F., and A. Lanzavecchia. 1994. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J. Exp. Med. 179:1109-1118.
23. Schols, D., R. Pauwels, F. Vanlangendonck, J. Balzarini, and E. De Clercq. 1988. A highly reliable, sensitive, flow cytometric/fluorometric assay for the evaluation of the anti-HIV activity of antiviral compounds in MT-4 cells. J. Immunol. Methods 114:27-32.
24. Spira, A. I., P. A. Marx, B. K. Patterson, J. Mahoney, R. A. Koup, S. M. Wolinsky, and D. D. Ho. 1996. Cellular targets of infection and route of viral dissemination after an intravaginal inoculation of simian immunodeficiency virus into rhesus macaques. J. Exp. Med. 183:215-225.
25. Squires, K. E. 2001. An introduction to nucleoside and nucleotide analogues. Antivir. Ther. 6(Suppl. 3):1-14.
26. Vanham, G., D. Davis, B. Willems, L. Penne, L. Kestens, W. Janssens, and G. van der Groen. 2000. Dendritic cells, exposed to primary, mixed phenotype HIV-1 isolates preferentially, but not exclusively, replicate CCR5-using clones. AIDS 14:1874-1876.
27. Vanham, G., L. Penne, H. Allemeersch, L. Kestens, B. Willems, G. van der Groen, K. T. Jeang, Z. Toossi, and E. Rich. 2000. Modeling HIV transfer between dendritic cells and T cells: importance of HIV phenotype, dendritic cell-T cell contact, and T-cell activation. AIDS 14:2299-2311.
28. Van Herrewege, Y., J. Michiels, J. Van Roey, K. Fransen, L. Kestens, J. Balzarini, P. Lewi, G. Vanham, and P. Janssen. 2004. In vitro evaluation of nonnucleoside reverse transcriptase inhibitors UC-781 and TMC120-R147681 as human immunodeficiency virus microbicides. Antimicrob. Agents Chemother. 48:337-339.
29. Van Herrewege, Y., L. Penne, C. Vereecken, K. Fransen, G. van der Groen, L. Kestens, J. Balzarini, and G. Vanham. 2002. Activity of reverse transcriptase inhibitors in monocyte-derived dendritic cells: a possible in vitro model for postexposure prophylaxis of sexual HIV transmission. AIDS Res. Hum. Retrovir. 18:1091-1102.
30. Wainberg, M. A. 2003. HIV resistance to nevirapine and other non-nucleoside reverse transcriptase inhibitors. J. Acquir. Immune. Defic. Syndr. 34(Suppl. 1):S2-S7.